Today: 6 November 2025
Subscribe
Browse Category

Cancer Research News 26 September 2025 - 18 October 2025

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” news.samsung.com. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic adults. Recently, two developments have driven the stock: Samsung’s strategic deal (announced Oct. 16) and positive trial data (released at ESMO). These moves suggest GRAIL is gaining traction, but they also highlight the challenges ahead in turning cutting-edge science into
18 October 2025
 ·  ·  ·  ·  · 
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share ts2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singapore ts2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technology tradingview.com prnewswire.com. Investors cheered the
17 October 2025
 ·  ·  ·  ·  · 
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Korea investing.com prnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&T prnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company
16 October 2025
 ·  ·  ·  ·  · 
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.
16 October 2025
 ·  ·  ·  · 
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20 sec.gov. In VIRAGE, the oncolytic adenovirus VCN-01 is given with gemcitabine/nab‑paclitaxel standard chemotherapy. Interim abstract data (recently filed with the SEC) show that VCN-01 + chemotherapy substantially improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone sec.gov sec.gov. Patients receiving VCN-01 saw median OS up to
15 October 2025
 ·  ·  ·  · 
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 (a personalized cancer vaccine for advanced melanoma) at the ESMO Congress in Berlin globenewswire.com. The October presentation (oral session Oct 17, webinar Oct 22) will cover efficacy, immunogenicity, safety, best overall response, and T‑cell response durability of EVX-01 plus Merck’s KEYTRUDA® globenewswire.com. Earlier one-year interim results showed a 69% overall response rate and tumor reduction in 15 of 16 patients globenewswire.com, highlighting the vaccine’s promise. Evaxion’s
15 October 2025
 ·  ·  ·  ·  · 
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Analysis: GRAIL’s stock performance reflects a wave of optimism about its Galleri cancer-screening test and pending trial results. In late September it broke out to new highs, aided by momentum and positive chatter (e.g. a StocksToTrade report noted a 17.93% jump on Sept 29 as MCED excitement grew stockstotrade.com). The company itself is pushing the narrative: GRAIL President Dr. Josh Ofman proclaims Galleri’s data will usher in a “transformative era for cancer screening,” detecting cancers earlier “when they can be easier to treat and are potentially curable” grail.com. For context, GRAIL has a unique profile. It straddles biotech and diagnostics:
3 October 2025
 ·  ·  ·  ·  · 
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered testing service for specialists treating leptomeningeal metastases (LM)—a devastating complication of advanced cancers. GlobeNewswire What the test does. The CNSide platform supports rapid diagnosis, treatment monitoring and guidance in LM. Plus Therapeutics reports >11,000 tests performed across 120+ institutions since
26 September 2025
 ·  ·  ·  ·  ·  · 
1 2
Go toTop